我省药物警戒工作 再受国家药监局通报表扬

Core Viewpoint - The Anhui Provincial Drug Administration has been recognized by the National Medical Products Administration for its outstanding performance in drug vigilance work in 2025, marking the third time it has received such acknowledgment [1]. Group 1: Drug Vigilance Work - The Anhui Provincial Drug Administration has implemented comprehensive measures to enhance the drug vigilance system, including clearer regulatory guidelines and internal audit guidelines for drug license holders [2]. - The coverage rate of drug vigilance inspections in the region exceeds 40%, with a focus on addressing common deficiencies found during inspections [2]. - The establishment of adverse drug reaction monitoring points has improved risk monitoring and response measures, including timely communication and production suspension when necessary [2]. Group 2: Training and Capacity Building - The provincial drug administration has organized online training for drug vigilance inspectors and conducted competitions to foster a competitive learning environment, significantly enhancing the capabilities of regulatory personnel [2]. Group 3: Future Directions - The Anhui Provincial Drug Administration plans to continue implementing the National Medical Products Administration's requirements for drug vigilance, aiming to improve risk prevention accuracy and regulatory efficiency with stricter standards and practical measures [3].